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Background
Transthyretin (TTR) is an amyloidogenic tetrameric protein,
present in human plasma, associated with several familial
amyloidoses. Variability of TTR is not only due to point
mutations in the encoding gene but also to post-transla-
tional modifications (PTMs) at Cys10, being the most com-
mon PTMs the S-sulfonation, S-glycinylcysteinylation,
S-cysteinylation and S-glutathionylation. It is thought that
PTMs at Cys10 may play an important biological role in the
onset and pathological process of the amyloidosis. Recently
we reported the development of a methodology for quantifi-
cation of PTMs in serum samples, as well as for the deter-
mination of serum TTR levels, from healthy (wt-TTR) and
ATTR V30M individuals which involves an enrichment
step by immunoprecipitation followed by mass spectrome-
try analysis of (i) the intact TTR protein and (ii) targeted
LC-MS analysis of peptides carrying the PTMs of interest
(M Vilà-Rico et al. Analysis of post-translational modifica-
tions in human transthyretin associated with familial amy-
loidotic polyneuropathy by targeted LC-MS and intact
protein MS. Journal of Proteomics (2015) in press). Analysis
of serum samples by the combination of the two methods
affords complementary information on the relative and
absolute amounts of the selected TTR PTM forms.
Methods
We aimed at describing the applicability of our mass
spectrometry methodology among healthy controls and
V30M-TTR patients (cases) at different disease stages
followed at our institution and other three spanish
health facilities. Inclusion criteriae for cases consisted of
a positive genetic testing for V30M-TTR status and a
signed ethics’ committee approved informed consent.
Mass spectrometric analysis was performed as detailed
in our previouis work.
Results
A total of 50 healthy controls and 29 patients were
included after signing the informed consent. Demographic
and clinical characteristics were gathered and correlated to
the proteomic analysis profile according to our validated
methodology. Significant differences were found for total
TTR as well as for specific TTR Cys-10 PTMs between
the different V30M ATTR stages as well as between con-
trols and symptomatic patients.
Conclusion
Quantification of wt:V30M TTR ratio and quantification
of Cys-10 PTM.
Isoforms is a feasible, reproducible and robust method
by intact TTR and targeted LC-MS in the TTR V30M
population. Significant differences for wt:V30M TTR
ratio as well as for some specific PTMs have been found
in a small cohort of V30M-TTR patients at different
ATTR stages. These results need to be confirmed in a
bigger cohort of patients with ATTR.
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